Reports Q2 revenue $95.4M, consensus $86.66M. “In Q2 2025, we continued our momentum by delivering robust Q2 results, achieving our highest net product revenue quarter ever for HEPLISAV-B, while further growing our market share leading position in the U.S. adult hepatitis B vaccine market,” said Ryan Spencer, CEO. “Our vaccine pipeline remains on track, with key clinical milestones achieved or expected this year across multiple programs. We look forward to reporting our top-line Phase 1/2 trial results for our novel shingles program in the coming weeks, an opportunity to further demonstrate a potential best-in-class profile for this program with the potential to disrupt the multi-billion-dollar shingles vaccine market.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DVAX: